MedTrace Logo

Differential Expression of Cytokines, Transcriptome and miRNA in Coronavirus Disease 2019 (COVID-19) Egyptian's Patients

NCT04583566 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2020-10-14

No results posted yet for this study

Summary

The aim of this effort is to study host-pathogen interaction in Egyptian patients infected with COVID-19. The investigators will perform genome-wide miRNA and transcriptome screens in the infected patients along with healthy ones for comparison. All types of cytokines play pivotal roles in immunity, including the responses to different viral infections. Therefore, The investigators will study the cytokines profile in response to that infection. By comparing miRNA and transcriptome screens along with cytokines profiles, an important molecule might be identified that could play role in the inhibition of the COVID-19 outbreak. In addition, this information will help us gaining awareness of the immune process and knowing about the genes involved in the immune response against COVID-19 with an emphasis on the expression of cytokines.

Conditions

  • Corona Virus Infection

Interventions

GENETIC

COVID-19 Diagnostic and Assessment Tests

Complete Blood Count (CBC), Differential leukocytes, D-dimer, C-Reactive Protein, Polymerase Chain Reaction (PCR) Test, Ferritin level, Cytokines Profile, Transcriptome Analysis, miRNA Analysis.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Mohammed Eid, Doctor · Botany and Microbiology Department, Faculty of Science, Tanta University Tanta

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-04
Primary Completion
2021-10-03
Completion
2022-10-03

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04583566 on ClinicalTrials.gov